Hims & Hers Health
Rating
Hold
Hold for Long-Term Compounding
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and personalised compounded prescriptions — narrow brand moat, expanding clinical footprint, real regulatory tail risk.
Hims's moat is brand recognition + vertical pharmacy operations in telehealth subscription — real but narrow, with regulatory exposure to compounded GLP-1 fluctuations:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in these categories are durable in normal market conditions, with subscriber retention in established categories averaging 12+ months.
- Vertical Pharmacy and Compounding Operations: Hims operates its own 503A/503B-style compounding pharmacies, allowing personalised GLP-1 and dermatology formulations. The April 2025 FDA shortage delisting forced compounded semaglutide off the market, but Hims has pivoted to oral GLP-1 personalisation and licensed Wegovy distribution — narrower but legal channel.
- Clinical Network Scale: Hims contracts with a national network of providers, allowing rapid intake-to-prescription on a single subscription stack. Switching costs for the patient are low but the convenience-and-pricing UX advantage vs traditional telehealth is real.
Ten Moats Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory and competitive. The thesis is execution-and-category-expansion, not durable franchise economics, appropriately sized as speculative growth.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data accumulating across 3M+ patients is real, though monetisation pathways limited by HIPAA and consent.
Telehealth and compounding regulation is fluid; the April 2025 GLP-1 compounding ban demonstrated the franchise's regulatory exposure.
N/A — DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and personalised compounded prescriptions — narrow brand moat, expanding clinical footprint, real regulatory tail risk.
Growth Score
FY26 revenue guide $2.4-2.5B (+45-50% YoY); subscribers ~3M. Weight-loss category remains the swing factor — branded Wegovy distribution licence + oral GLP-1 personalisation are growing but at lower margin than 2024 compounded semaglutide. New categories (testosterone, women's health) extend the platform.
Valuation Score
At ~$50 HIMS trades at ~50× FY26 EPS — a hypergrowth multiple that prices in continued execution and expanding categories. Volatility around regulatory news cycles is high; the multiple has shown 40%+ drawdowns multiple times.
The DTC Telehealth Brand Moat
Hims's moat is brand recognition + vertical pharmacy operations in telehealth subscription — real but narrow, with regulatory exposure to compounded GLP-1 fluctuations:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in these categories are durable in normal market conditions, with subscriber retention in established categories averaging 12+ months.
- Vertical Pharmacy and Compounding Operations: Hims operates its own 503A/503B-style compounding pharmacies, allowing personalised GLP-1 and dermatology formulations. The April 2025 FDA shortage delisting forced compounded semaglutide off the market, but Hims has pivoted to oral GLP-1 personalisation and licensed Wegovy distribution — narrower but legal channel.
- Clinical Network Scale: Hims contracts with a national network of providers, allowing rapid intake-to-prescription on a single subscription stack. Switching costs for the patient are low but the convenience-and-pricing UX advantage vs traditional telehealth is real.
Ten Moats Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory and competitive. The thesis is execution-and-category-expansion, not durable franchise economics, appropriately sized as speculative growth.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data accumulating across 3M+ patients is real, though monetisation pathways limited by HIPAA and consent.
Telehealth and compounding regulation is fluid; the April 2025 GLP-1 compounding ban demonstrated the franchise's regulatory exposure.
N/A — DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Growth Analysis
Growth Drivers
Key Risk
If FDA enforcement against personalised compounding tightens further or state regulators impose telehealth-prescription restrictions on GLP-1 in 2026-27, the weight-loss category could decline 30-40% and the margin profile compresses materially.
Score Derivation
Base 90 (>30% CAGR hypergrowth) + 3 platform extension (women's health, testosterone, weight-loss next-gen) - 7 regulatory/category risk (compounded GLP-1 ban, ongoing FTC/state-AG scrutiny) - 6 margin compression (branded GLP-1 lower margin than compounded) = 80
Price Scenarios (12–24 Months)
Valuation Multiples
| Forward P/E (FY26) | ~50× |
| Forward P/E (FY27) | ~32× |
| Price / Sales (FY26) | ~4.5× |
| PEG Ratio | ~1.1× |
| FCF Yield | ~3% |
Valuation discounts none of the regulatory or category-shift risk; the equity is a high-volatility growth-and-execution position rather than a quality compounder.
Approximate figures as of May 2026.
Where We Are vs Targets
Loading live price…
FDA compounding enforcement tightens further, weight-loss category declines, multiple compresses to 20-25× on growth deceleration.
- FDA or state AG enforcement restricts personalised GLP-1 telehealth prescribing
- Branded Wegovy distribution disappoints on margin and subscriber retention
- Subscriber growth slows below 25% YoY as marketing CAC rises
FY26 revenue $2.5B at high end, subscriber growth +35%, EBITDA margin expands to 14%, multiple holds at 35×.
- Subscriber base reaches 3.5M end-FY26
- Weight-loss category settles into branded + oral mix at sustainable margin
- New categories (women's health, testosterone) reach 15%+ of revenue
Hims becomes the dominant DTC chronic-care platform, EBITDA margin expands toward 20%, multiple sustains 40×+ on durable growth.
- Subscriber base exceeds 4.5M with NRR >115%
- International expansion (UK, Canada, EU pilot) materialises in 2026-27
- Platform category mix diversifies the regulatory tail-risk concentration